Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for UNITED THERAPEUTICS (UTHR) over the last 15 years, with Sep 2025 value amounting to $214.6 million.

  • UNITED THERAPEUTICS's Other Non-Current Liabilities rose 44.22% to $214.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.6 million, marking a year-over-year increase of 44.22%. This contributed to the annual value of $181.9 million for FY2024, which is 133.80% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Other Non-Current Liabilities stood at $214.6 million for Q3 2025, which was up 3.52% from $207.3 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Other Non-Current Liabilities' 5-year high stood at $215.2 million during Q1 2025, with a 5-year trough of $67.4 million in Q3 2023.
  • Its 3-year average for Other Non-Current Liabilities is $136.5 million, with a median of $100.0 million in 2023.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Other Non-Current Liabilities slumped by 34.88% in 2023, and later spiked by 133.80% in 2024.
  • UNITED THERAPEUTICS's Other Non-Current Liabilities (Quarterly) stood at $104.8 million in 2021, then declined by 0.19% to $104.6 million in 2022, then dropped by 25.62% to $77.8 million in 2023, then skyrocketed by 133.80% to $181.9 million in 2024, then surged by 44.22% to $214.6 million in 2025.
  • Its last three reported values are $214.6 million in Q3 2025, $207.3 million for Q2 2025, and $215.2 million during Q1 2025.